Researchers from Pretzel Therapeutics Inc. and the University of Gothenburg have published new insights on how mutations in the POLG gene affect its functionality and are tied to PolG diseases. They have also presented a compound for its potential treatment, PZL-A. They published their results in Nature on April 9, 2025. Read More

Praetego Inc. and University of California San Diego scientists reported preclinical results for the new small-molecule amadorin PTG-630, a brain-penetrant drug candidate that inhibits the formation of advanced glycation end-products (AGEs). Read More

Boehringer Ingelheim Pharma GmbH & Co KG and Cue Biopharma Inc. have signed a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501, a differentiated B-cell depletion therapy for autoimmune diseases. Read More

Researchers from AC Immune SA recently presented the discovery of ACI-21018, a novel α-synuclein aggregation inhibitor developed using AC Immune’s proprietary Morphomer platform. Read More

The etiology of epilepsy, as well as its pathology, still remains evasive. The role that FK506-binding protein 51 (FKBP51) might play in this disease was investigated in a murine model of kainic acid-induced excitotoxic brain injury. Read More

1st Biotherapeutics Inc. has joined The Michael J. Fox Foundation for Parkinson’s Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) program. Read More

Writing in Nature, researchers from China Pharmaceutical University and Shandong University have revealed the discovery of a new polyene antifungal antibiotic, mandimycin. Read More

Simcere Zaiming Pharmaceutical Co. Ltd. has received clinical trial approval from China’s National Medical Products Administration (NMPA) for the company’s antibody-drug conjugate (ADC), SIM-0686, for FGFR2b-positive, locally advanced or metastatic solid tumors. Read More

PMV Pharmaceuticals Inc. has disclosed cellular tumor antigen p53 (TP53) (mutant) stabilizers reported to be useful for the treatment of cancer. Read More

Astrogen Co. Ltd. has synthesized prodrugs of 4-hydroxy atomoxetine reported to be useful for the treatment of aphasia, apraxia, attention deficit hyperactivity disorder, cognitive disorders, Alzheimer’s disease, Parkinson’s disease and ischemic stroke. Read More

Overexpression of focal adhesion kinase (FAK) has been observed in several types of cancer, including gastric, esophageal and colorectal cancers. Several FAK inhibitors have advanced to clinical evaluation for the treatment of cancer, however, none have entered the market. Read More

Gilgamesh Pharmaceuticals Inc. has identified phenalkylamine compounds acting as 5-HT2A receptor agonists reported to be useful for the treatment of psychiatric disorders. Read More

Disc Medicine Inc. has divulged glycine transporter-1 (GlyT-1) inhibitors reported to be useful for the treatment of hematological disorders. Read More

Researchers from Tridem Bioscience GmbH & Co. KG provided details on the development of TRB-001, an anti-α-synuclein construct consisting of a B-cell epitope derived from human α-synuclein (SNCA), conjugated to CRM197 and C-type lectin (CLEC) β-glucan. Read More

Huons Global Co. Ltd. has described reversible H+/K+ ATPase inhibitors, particularly acid pump antagonists (APA), reported to be useful for the treatment of gastric and duodenal ulcers, gastritis, gastroesophageal reflux disease, Helicobacter pylori infection and Zollinger-Ellison syndrome. Read More